Condition: Intermediate Age-Related Macular Degeneration · Sponsor: Smilebiotek Zhuhai Limited
This is a phase III randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.
This description comes directly from the study's public registry record.
Hong Dai · 010-85132171 · Dai-hong@x263.net
Always discuss trial participation with your own doctor first.
| Beijing Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07189169